美国 · 平台与数据 · Stocktwits

AstraZeneca CEO Sees Over $20B Potential From 2027 Drug Trial Readouts – AZN Stock Eyes Breakout After Q3 Earnings Beat

来源：Stocktwits · 美国 9 小时前

AstraZeneca reported a 7% increase in Q3 revenue to $16.21 billion, beating Wall Street estimates of about $16 billion, according to Fiscal.ai.

在 Stocktwits 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (stocktwits.com)

推荐阅读

Gilead Sciences, Inc. (NASDAQ:GILD) Shareholders to Collect $0.82 Quarterly Dividend

Acumen plunges on mid-stage trial setback for Alzheimer’s candidate

The Motley Fool

Invitation Homes: 3 Key Takeaways for Long-Term Investors

‘Fancy cars hold no appeal’: We have a 99% chance of outliving our life savings. Why not spend, spend, spend?

Hilton Grand Vacations announces $200 million accelerated share repurchase

Best Tech Stocks Right Now